Treatment costs of venlafaxine and selective serotonin-reuptake inhibitors for depression and anxiety

Managed Care Interface

Volumn 15, Issue 6, 2002, Pages 24-30

  Wan, George J ^a   Crown, William H ^a   Berndt, Ernst R ^a   Finkelstein, Stan N ^a   Ling, Davina ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; ANXIETY NEUROSIS; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG COST; DRUG FORMULATION; DRUG RELEASE; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; PRESCRIPTION;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; LONGITUDINAL STUDIES; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; UNITED STATES;

EID: 0036280580     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Health economics and cost implications of anxiety and other mental disorders in the United States
2. The economic burden of depression in 1990
3. The economic burden of anxiety disorders in the 1990s
4. Cost of anxiety disorders: Impact of comorbidity
5. Health and disability costs of depressive illness in a major U.S. corporation
6. Depression in managed care: Costs of selective serotonin-reuptake inhibitors
7. Variation in treatment compliance and costs by antidepressant class: Analysis in an HMO setting
8. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy: Following selective serotonin-reuptake inhibitor therapy for depression
9. One-year costs of second-line therapies for depression
10. Long-term costs of treatment for depression: Impact of drug selection and guideline adherence
11. Managing depression in medical outpatients
12. Overview of patient compliance with medication dosing: A literature review
13. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence
14. The role of SSRI antidepressants for treating depressed patients in the California Medicaid (Medi-Cal) program
15. Predictors of a medical-offset effect among patients receiving antidepressant therapy
16. An examination of the relationship between non-depression-related costs and uninterrupted treatment
17. Retrospective analysis of the health care costs of bupropion sustained release in comparison with other antidepressants
18. Antidepressant selection for major depressive disorder: The budgetary impact on managed care
19. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders
20. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder
21. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom
22. A pharmacoeconomic evaluation of major depressive disorder (Italy)
23. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): A comparison of cost-effectiveness between venlafaxine, SSRIs, and TCAs
24. The health economic impact of antidepressant usage from a payer's perspective: A multinational study
25. Evolution of remission as the new standard in the treatment of depression
26. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: Remission, recovery, relapse, and recurrence
27. Recovery from depression, work productivity, and health care costs among primary care patients
28. Remission rates during treatment with venlafaxine or selective serotonin-reuptake inhibitors